Boniva (Ibandronate Sodium Hydrate)
Ibandronate Sodium Monohydrate 3.375mg
Injections · Prescription medication
KS Pharmaceutical Co., Ltd.
MFDS item code 202001286 · Notified 2020.02.24 · Insurance code 059000621
Treatment of osteoporosis in postmenopausal women
This medication is used for the treatment of osteoporosis in postmenopausal women.
Administer 3mg by intravenous injection over 15 - 30 seconds once every 3 months. Patients should also take calcium and vitamin D. If a dose is missed on the scheduled dosing date, administer it as soon as possible, and then continue regular dosing at 3-month intervals from that date. Patients with hepatic impairment: No dose adjustment is necessary. No dose adjustment is necessary for patients with mild or moderate renal impairment whose serum creatinine is 200 µmol/L(2.3mg/dL) or less or whose creatinine clearance is 30ml/min or more. This drug is not recommended for patients whose serum creatinine exceeds 200 µmol/L(2.3mg/dL) or whose creatinine clearance is less than 30ml/min, as there is insufficient clinical experience in these patients. Elderly patients: No dose adjustment is necessary.
Efficacy and safety in children 18 years of age and younger have not been studied.
This medication should be administered solely via intravenous injection; care must be taken to avoid injecting around arteries or veins as this can cause tissue damage. It should not be used in patients with an allergy to this drug or any of its components, or in patients with untreated hypocalcemia. During treatment with this drug, side effects such as gastritis, diarrhea, abdominal pain, indigestion, nausea, constipation, muscle and joint pain, headache, and rash may occur. In some patients, flu-like symptoms, fatigue, and injection site reactions may develop; these symptoms are usually temporary and mild. This drug may temporarily lower calcium levels, so it is important to treat hypocalcemia or disorders of bone and mineral metabolism before administration, and to ensure adequate intake of calcium and vitamin D. Patients requiring dental work should have oral examinations in advance and should avoid excessive dental procedures during treatment. Rare cases of osteonecrosis of the jaw or ear canal have been reported in patients receiving this drug; immediate consultation with a physician is advised if any related symptoms occur. If there is pain in the thigh or groin, the possibility of atypical femoral fracture should be suspected and further examination should be conducted. This medication is not metabolized in the liver and is primarily eliminated through the kidneys, thus regular monitoring is required for patients with impaired kidney function. It is preferable that this drug is not used by pregnant or breastfeeding women, and safety in children has not been established. In cases of overdose, electrolyte abnormalities such as hypocalcemia may occur, thus immediate medical treatment and monitoring are necessary. This drug should not be mixed with other calcium-containing solutions and must be administered solely via intravenous injection. After use, do not reuse the injection needle and syringe; dispose of them safely.
Gastritis, diarrhea, abdominal pain, dyspepsia, nausea, constipation, musculoskeletal pain, joint pain, muscle pain, influenza-like disease, fatigue, headache, rash, bone pain, weakness, injection site reaction, phlebitis, thrombophlebitis, hypersensitivity reaction, angioedema, facial swelling, edema, urticaria, osteonecrosis of the jaw and external auditory canal, uveitis, episcleritis, scleritis, anaphylactic reaction, shock, exacerbation of asthma, Stevens-Johnson syndrome, erythema multiforme, vesicular dermatitis, atypical stress fractures, intertrochanteric femoral fractures, dizziness, optic atrophy, lower motor neuron lesions, tremor, nonspecific gastrointestinal disease, benign gastrointestinal tumors, toothache, hyperventilation, cough, dyspnea, laryngitis, vaginitis, menopausal symptoms, multiple organ failure, death, insomnia, anxiety, tinnitus, hearing loss, hypothyroidism, lipoma, ocular hemorrhage, heart failure, urinary disorders, hematuria, skin desquamation, acute renal failure
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a sealed container to prevent exposure to air or humidity. The storage temperature should be maintained between 1 and 30 degrees Celsius (room temperature) to preserve its efficacy.
The injection is a colorless, transparent solution contained in a colorless, transparent glass prefilled syringe with a single-use needle attached.
3 milliliters/prefilled syringe
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Ibandronate Sodium Monohydrate 3.375mg
Injections · Prescription medication
KS Pharmaceutical Co., Ltd.

Ibandronate Sodium Monohydrate 168.75mg
Tablet · Prescription medication
Jeil Pharmaceutical Co., Ltd.
Ibandronate Sodium Monohydrate 3.375mg
Solution · Prescription medication
Jeil Pharmaceutical Co., Ltd.

Ibandronate Sodium Monohydrate 168.75mg
Tablet · Prescription medication
Chodang Pharmaceutical Co., Ltd.

Ibandronate Sodium Monohydrate 168.75mg
Tablet · Prescription medication
Shinpoong Pharmaceutical Co., Ltd.

Ibandronate Sodium Monohydrate 168.75mg
Tablet · Prescription medication
Ajou Pharmaceutical Co., Ltd.

Ibandronate Sodium Monohydrate 168.75mg
Tablet · Prescription medication
Aliko Pharmaceutical Co., Ltd.

Ibandronate Sodium Monohydrate 168.75mg
Tablet · Prescription medication
Teragen Etex Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.